Together, these critical data demonstrate that ErbB2+ cancer cells are preferentially sensitive to the anti-cancer effects of ganetespib, particularly on cell proliferation, which indicate the fundamental role of ErbB2 in the targeted effects of ganetespib. This evidence concerns the gene ERBB2 and cancer.